William Y. Go, Ph.D.
Affiliations: | 2004 | University of California, San Diego, La Jolla, CA |
Area:
Immunology, Animal Physiology Biology, Molecular BiologyGoogle:
"William Go"Parents
Sign in to add mentorSteffan N. Ho | grad student | 2004 | UCSD | |
(The role of the mammalian osmotic stress response in adaptive immunity: New insights from studies of the NFAT5/TonEBP transcription factor.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Kamb A, Go WY. (2020) Cancer T-cell therapy: building the foundation for a cure. F1000research. 9: 1295 |
Locke FL, Rossi JM, Neelapu SS, et al. (2020) Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4: 4898-4911 |
Chen PH, Lipschitz M, Weirather JL, et al. (2020) Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T-cell therapy. Jci Insight |
Locke FL, Go WY, Neelapu SS. (2019) Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. Jama Oncology. 1-10 |
Rossi JM, Galon J, Chang E, et al. (2019) Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1 Clinical Trials. 79 |
Neelapu SS, Ghobadi A, Jacobson CA, et al. (2019) 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Biology of Blood and Marrow Transplantation. 25: S65 |
Lee DW, Santomasso BD, Locke FL, et al. (2018) ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation |
Locke FL, Ghobadi A, Jacobson CA, et al. (2018) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet. Oncology |
Locke FL, Ghobadi A, Lekakis LJ, et al. (2018) Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma. Journal of Clinical Oncology. 36: 3039-3039 |
Locke FL, Ghobadi A, Jacobson CA, et al. (2018) Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma. Journal of Clinical Oncology. 36: 3003-3003 |